Millennium Management LLC Raises Stock Position in Context Therapeutics Inc. (NASDAQ:CNTX)

Millennium Management LLC lifted its position in Context Therapeutics Inc. (NASDAQ:CNTX) by 24.2% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 178,718 shares of the company’s stock after buying an additional 34,835 shares during the period. Millennium Management LLC’s holdings in Context Therapeutics were worth $188,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of CNTX. Jane Street Group LLC purchased a new position in shares of Context Therapeutics in the 4th quarter worth approximately $29,000. Citadel Advisors LLC purchased a new position in shares of Context Therapeutics in the 4th quarter worth approximately $31,000. Landscape Capital Management L.L.C. purchased a new position in shares of Context Therapeutics in the 4th quarter worth approximately $94,000. Walleye Capital LLC grew its position in shares of Context Therapeutics by 51.7% in the 4th quarter. Walleye Capital LLC now owns 166,306 shares of the company’s stock worth $175,000 after buying an additional 56,651 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in shares of Context Therapeutics in the 4th quarter worth approximately $213,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Context Therapeutics Trading Up 5.2%

NASDAQ:CNTX opened at $0.65 on Friday. The company has a market cap of $58.54 million, a PE ratio of -0.72 and a beta of 1.86. Context Therapeutics Inc. has a twelve month low of $0.49 and a twelve month high of $2.75. The company’s 50 day moving average is $0.75 and its two-hundred day moving average is $0.91.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Wednesday, May 14th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05). As a group, analysts expect that Context Therapeutics Inc. will post -0.51 EPS for the current fiscal year.

Insider Buying and Selling at Context Therapeutics

In other news, CEO Martin A. Lehr bought 100,000 shares of the firm’s stock in a transaction that occurred on Monday, June 9th. The stock was purchased at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the purchase, the chief executive officer now directly owns 920,190 shares in the company, valued at approximately $644,133. This trade represents a 12.19% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Jennifer Lynn Minai-Azary bought 40,010 shares of the firm’s stock in a transaction that occurred on Friday, June 6th. The stock was purchased at an average price of $0.64 per share, with a total value of $25,606.40. Following the completion of the purchase, the chief financial officer now owns 80,010 shares in the company, valued at approximately $51,206.40. This trade represents a 100.03% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 160,010 shares of company stock worth $107,206. Company insiders own 2.80% of the company’s stock.

Analysts Set New Price Targets

CNTX has been the topic of several research analyst reports. William Blair reissued an “outperform” rating on shares of Context Therapeutics in a research report on Tuesday, April 29th. D. Boral Capital reissued a “buy” rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Thursday, May 8th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 target price on shares of Context Therapeutics in a research report on Friday, March 21st. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Context Therapeutics has an average rating of “Buy” and an average target price of $6.00.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.